To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: European Union Approves Dynepo (Erythropoietin) for Renal Disease-Related Anemia URL: http://www.pslgroup.com/dg/214F8E.htm Doctor's Guide March 26, 2002
CAMBRIDGE, MA -- March 26, 2002 -- Transkaryotic Therapies, Inc. today announced that the European Commission has granted marketing authorization of Dynepo™ (epoietin delta) for the fifteen countries of the European Union. Dynepo is a human erythropoietin for the treatment of anemia related to renal disease in patients receiving dialysis and in patients who have not yet undergone dialysis to elevate and maintain red blood cell production. Under a collaborative agreement, Aventis Pharma, the pharmaceutical company of Aventis S.A., is responsible for the development and marketing activities of Dynepo.
Dynepo, a fully human erythropoietin product, was developed using TKT's patented gene activation technology. Clinical testing in over 1,400 dialysis and pre-dialysis patients supported the approval of Dynepo as a treatment for anemia related to renal disease. A phase III study is ongoing to test Dynepo for anemia associated with cancer chemotherapy.
Erythropoietin is a hormone that stimulates the production of red blood cells and is used primarily as a treatment for anemia associated with renal disease or cancer chemotherapy. Globally, more than 700,000 patients with end-stage renal failure experience anemia. By stimulating red blood cell production, erythropoietin is beneficial in the management and improvement of anemia.
SOURCE: Transkaryotic Therapies, Inc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.